VGNX -- Variagenics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX -- Variagenics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (117)	2/1/2002 2:13:32 PM
From: scaram(o)uche	Read Replies (2) of 269

I have no bias. The studies could, for all I know, be complete busts. Or, they could change the nature of clinical testing, FOREVER......... * Enrollment was completed in the Company's second clinical study, STRENGTH II, marking another milestone for the Company that was completed within the timetable originally set. The STRENGTH studies are a key element of the Company's internal product development initiatives. Data analysis is on schedule for initial genetic correlations to be reported by the end of the first quarter of 2002 for STRENGTH I, with STRENGTH II data expected during the third quarter of 2002. Less than two months to go.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next